Amyotrophic Lateral Sclerosis

Novel outcome measures for ALS and SMA 3:26
Novel outcome measures for ALS and SMA
Marianne de Visser • 28 Sep 2021
Using antibodies and intrabodies to target pathogenic TDP-43 in ALS 6:05
Using antibodies and intrabodies to target pathogenic TDP-43 in ALS
Neil Cashman • 2 Aug 2021
MS research from EAN 2021 2:11
MS research from EAN 2021
Massimo Filippi • 17 Jun 2021
Collaboration between neurology and palliative care services in ALS 2:06
Collaboration between neurology and palliative care services in ALS
David Oliver • 11 Jun 2021
Palliative care improves QoL in advanced neurodegenerative disorders 4:46
Palliative care improves QoL in advanced neurodegenerative disorders
David Oliver • 11 Jun 2021
AMX0035 in ALS: long-term survival analysis of the CENTAUR trial 3:40
AMX0035 in ALS: long-term survival analysis of the CENTAUR trial
Sabrina Paganoni • 15 Apr 2021
A new era in the discovery of ALS treatments 0:56
A new era in the discovery of ALS treatments
Sabrina Paganoni • 15 Apr 2021
CNM-Au8 gold nanocatalysts to slow disease progression in ALS 3:11
CNM-Au8 gold nanocatalysts to slow disease progression in ALS
Robert Glanzman • 1 Mar 2021
The perpetual multi-center multi-regimen Healy-ALS Platform trial 0:46
The perpetual multi-center multi-regimen Healy-ALS Platform trial
Robert Glanzman • 1 Mar 2021
Debating controversies in ALS 2:54
Debating controversies in ALS
Ettore Beghi • 27 Oct 2020
COVID-19: managing neurodegenerative diseases in southern Italy 6:13
COVID-19: managing neurodegenerative diseases in southern Italy
Giancarlo Logroscino • 22 Oct 2020
Potential environmental triggers of sporadic ALS 2:32
Potential environmental triggers of sporadic ALS
Peter Spencer • 19 Oct 2020
The reconstructed cohort design: tracking rare neurodegenerative diseases 4:40
The reconstructed cohort design: tracking rare neurodegenerative diseases
Giancarlo Logroscino • 22 Oct 2020
Potential toxins causing sporadic ALS: nitrosamines and hydrazines 2:40
Potential toxins causing sporadic ALS: nitrosamines and hydrazines
Peter Spencer • 19 Oct 2020
Identifying new therapeutic targets for neurodegenerative diseases 1:35
Identifying new therapeutic targets for neurodegenerative diseases
Bart De Strooper • 19 Oct 2020
Cycad toxins driving the ALS-Parkinsonism-Dementia complex 2:40
Cycad toxins driving the ALS-Parkinsonism-Dementia complex
Peter Spencer • 19 Oct 2020
The content of VJNeurology is intended for healthcare professionals